Get the Daily Brief
Latest Biotech News
Regulatory approvals and withdrawals
The FDA cleared Ultragenyx’s one-time AAV gene therapy Genglycos (pariglasgene brecaparvovec; DTX-401) for glycogen storage disease type Ia (GSDIa), giving the company its first marketable gene...
Oncology drug pipeline: early clinical progress and new study signals
Zanidatamab is generating momentum in early-stage HER2-positive breast cancer with NeoZanHER, a NeoZanHER phase 2 trial evaluating the next-generation dual-attack antibody zanidatamab in patients...
Immuno-oncology and bispecific antibodies
China’s NMPA accepted the NDA for opamtistomig (LBL-024), a PD-L1/4-1BB-directed bispecific antibody, as monotherapy for previously treated advanced extrapulmonary neuroendocrine carcinoma...
Clinical outcomes: diagnostics, digital health, and trial readouts
The FDA cleared PrecivityAD2, a blood test designed to detect Alzheimer’s-linked amyloid pathology, positioning it as an aid in evaluating Alzheimer’s disease. The move adds a new objective layer...
Trial and regulation scrutiny: clinical trial workforce and study-start pressure
A policy shift at NIH is set to remove a key training pathway for clinical trialists by ending support for K awards tied to clinical trial required announcements. The analysis highlights that...
Company financing and reverse mergers
Ambros Therapeutics and Werewolf Therapeutics agreed to merge via an all-stock deal, raising $150 million in a private placement to fund Ambros’ phase 3 push for a rare disease pain therapy...
Diabetes and GLP-1 safety: tuberculosis risk signal
A Nature Communications study examined whether GLP-1 receptor agonists affect tuberculosis risk in people with type 2 diabetes. The analysis, led by KM Liao, JY Wu, and CC Lai, sits at the...
Cutting-edge platform tech: AI + single-cell and bioprocessing tools
Deepcell and Gilead teamed up to develop a custom AI foundation model for Chinese hamster ovary (CHO) cell line development using morphology data. The partnership leverages Deepcell’s REM-I...
Oncology discovery and targeted mechanisms
Stanford Medicine researchers reported a molecular-glue style strategy that converts a cancer driver into a built-in kill switch, eradicating aggressive human lymphoma tumors in mice. The...
Biotech innovation in rare disease and advanced therapeutics
Silence Therapeutics advanced divesiran in polycythemia vera after positive Phase II results from SANRECO (NCT05499013). The siRNA therapy met the primary endpoint, delivering an 88% response rate...
Regulatory fallout and accelerated clinical trial scrutiny in China
China’s fast-track investigator-initiated trial model drew scrutiny after reports of three deaths in expedited trials, spotlighting oversight and trust gaps in the system. The deaths have raised...
FDA approves first-in-class gene therapy for ultra-rare glycogen storage disease type Ia
The U.S. FDA cleared Ultragenyx’s one-time gene therapy Genglycos (pariglasgene brecaparvovec; DTX-401) for glycogen storage disease type Ia (GSDIa) in patients aged 8 and older, marking both an...
China NMPA accepts NDA for 4-1BB PD-L1 bispecific opamtistomig in advanced extrapulmonary neuroendocrine carcinoma
China’s NMPA accepted the new drug application for opamtistomig (LBL-024), a PD-L1/4-1BB–directed bispecific antibody, as monotherapy for previously treated advanced extrapulmonary neuroendocrine...
Moderna’s personalized cancer vaccine posts topline results as investors react
Moderna’s personalized cancer vaccine posted topline results in a segment dominated by cancer-vaccine readouts, reinforcing the company’s push into individualized immunotherapies. The weekly...
Breakthrough therapy designation in oncology pipeline: NeoZanHER phase 2 data for neoadjuvant zanidatamab
Zanidatamab showed promise in early-stage HER2-positive breast cancer in the NeoZanHER phase 2 trial, a next-generation approach aimed at treating patients before surgery. The study, published in...
Silence Therapeutics advances siRNA divesiran in polycythemia vera with positive Phase II
Silence Therapeutics reported positive Phase II trial results for divesiran, an siRNA targeting TMPRSS6 in polycythemia vera (PV). The SANRECO trial met its primary endpoint, with an 88% response...
Genentech commits $750M to expand drug-delivery device manufacturing
Genentech announced a $750 million investment in a new drug delivery device facility at its Hillsboro, Oregon site, targeting expanded production capacity for delivery technologies used across its...
Regeneron scores FDA clearance for Pasatru in fibrodysplasia ossificans progressiva
The FDA cleared Regeneron’s Pasatru (garetosmab) for fibrodysplasia ossificans progressiva (FOP), setting up a commercial race against Ipsen’s Sohonos. The approval follows Phase 3 results...
Next wave diagnostics and real-world testing: FDA clears blood test to assess Alzheimer’s amyloid pathology
The FDA cleared PrecivityAD2, a blood test designed to detect Alzheimer’s-linked amyloid pathology and to be marketed as an aid in evaluating Alzheimer’s disease. The assay was developed from...
DeepCyte launches DeeTox Atlas to model drug toxicity mechanisms at single-cell resolution
DeepCyte launched DeeTox Atlas, a single-cell metabolomic reference map of drug toxicity mechanisms intended to support toxicity interpretation and earlier liability detection. The company said...